Celiprolol is a beta-blocker for the management of hypertension and angina pectoris. It is simultaneously a selective β1 receptor antagonist, a β2 receptor partial agonist and a weak α2 receptor antagonist.
- Mechanism
- Curator reviewed
Celiprolol is a vasoactive beta-1 selective adrenoceptor antagonist with partial beta-2 agonist activity. The beta-2 agonist activity is thought to account for its mild vasodilating properties. It lowers blood pressure in hypertensive patients at rest and on exercise. The effects on heart rate and cardiac output are dependent on the pre-existing background level of sympathetic tone. Under conditions of stress such as exercise, celiprolol attenuates chronotropic and inotropic responses to sympathetic stimulation. However, at rest minimal impairment of cardiac function is seen.
- Primary indication
- Celiprolol is indicated for the management of mild to moderate hypertension and effort-induced angina pectoris.Curator reviewed · 2 structured indications
- Formula / weight
- C20H33N3O4 · 379.501 g/mol (avg)
- Code names
- REV 5320 A · RHC-5320A · ST 1396 · UL/1677
Resolves to
JOATXPAWOHTVSZ-UHFFFAOYSA-NSMILESCCN(CC)C(=O)NC1=CC=C(OCC(O)CNC(C)(C)C)C(=C1)C(C)=OWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Celiprolol, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account